{"meta":{"query_hash":"9bdae3b7f519","filters":{"venue":"European Journal of Oncology Pharmacy"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/9bdae3b7f519","api":"https://metacan.xera.ac/api/v1/cohort?venue=European+Journal+of+Oncology+Pharmacy"},"results":[{"id":"W2978692898","doi":"10.1097/op9.0000000000000006","title":"Treatment options for patients with mantle cell lymphoma post-transplantation","year":2018,"lang":"en","type":"article","venue":"European Journal of Oncology Pharmacy","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Mantle cell lymphoma; Ibrutinib; Medicine; Autologous stem-cell transplantation; Oncology; Regimen; Internal medicine; Lymphoma; Randomized controlled trial; Refractory (planetary science); Leukemia; Biology","score_opus":0.02329371616774092,"score_gpt":0.31644314923921174,"score_spread":0.29314943307147084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978692898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012438289,0.9797147,0.0002807305,0.0029825713,0.00021073,0.00016896045,0.0005176364,0.000010782878,0.0036755977],"genre_scores_gemma":[0.23467365,0.75499463,0.0021262805,0.004894707,0.00061585894,0.00051283836,0.00110377,0.0000074296586,0.001070768],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999215,0.00037071024,0.00022241099,0.000042129075,0.00011150173,0.000038203838],"domain_scores_gemma":[0.9967642,0.002099089,0.00084902317,0.000034759752,0.00017626889,0.000076780314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013753283,0.00016418358,0.0009053421,0.0015692277,0.0002960748,0.00084862567,0.00037731332,0.0006585126,0.0074825035],"category_scores_gemma":[0.006578083,0.00009856712,0.0015135644,0.0015151954,0.00021793264,0.00095302577,0.00042012078,0.00074913865,0.00045178088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001669944,0.00034623005,0.010151452,0.23146772,0.0025952249,0.001307223,0.00054008234,0.00037574314,0.00089573266,0.0019207577,0.016877932,0.7318519],"study_design_scores_gemma":[0.0037922964,0.0039116074,0.06507161,0.46584877,0.017916812,0.012287645,0.0037221278,0.0005104624,0.002206675,0.009094028,0.41551372,0.00012415099],"about_ca_topic_score_codex":0.0008194677,"about_ca_topic_score_gemma":0.002312393,"teacher_disagreement_score":0.0074825035,"about_ca_system_score_codex":0.0004911794,"about_ca_system_score_gemma":0.0013275292,"threshold_uncertainty_score":0.025031447},"labels":[],"label_agreement":null}]}